Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 62

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Colorectal cancer

Recruiting

Study on Avelumab and Cetuximab for Patients with Metastatic Colorectal Cancer Who Have Previously Received Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale

Cancer fatigue

Recruiting

Study on Methylphenidate for Reducing Fatigue in Childhood Brain Tumor Survivors

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Methylphenidate
  • Sponsor:Odense University Hospital

Colon cancer

Recruiting

Study on the Effectiveness of Neoadjuvant Chemotherapy with Oxaliplatin and Capecitabine for Patients with Locally Advanced Colon Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Clinica Universidad De Navarra

Study of FG001 for Detecting Meningioma or Low-Grade Glioma in Patients Undergoing Neurosurgery

Recruiting
InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:FG001
  • Sponsor:Copenhagen University Hospital

Squamous cell carcinoma of skin

Recruiting

Study of nivolumab and ipilimumab combination therapy as an alternative to surgery and radiation in patients with skin squamous cell carcinoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Prostate cancer metastatic

Recruiting

Study of 177Lu-PSMA and Stereotactic Radiotherapy vs. Radiotherapy for Patients with Oligometastatic Prostate Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:177LU-PSMA-I&T
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Neoplasm malignant

Recruiting

Study on Dabrafenib, Trametinib, and Imatinib for Patients with Rare and Hard-to-Treat Cancers

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dabrafenib
  • Sponsor:Oslo University Hospital HF

Hairy cell leukaemia

Recruiting

Study of Vemurafenib and Rituximab for Untreated Hairy Cell Leukemia Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Universita Degli Studi Di Perugia

Chronic lymphocytic leukaemia+2

Recruiting

Study of IDP-121 for Patients with Relapsed or Refractory Multiple Myeloma, B-cell Lymphoma, or Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:IDP-121
  • Sponsor:Idp Discovery Pharma S.L.

Prostate cancer

Recruiting

Study on Lutetium (177Lu) Zadavotide Guraxetan for Prostate Cancer Patients with Biochemical Recurrence After Initial Curative Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Medical University Of Vienna

Colorectal cancer metastatic

Recruiting

Study on Cetuximab, Irinotecan, and Fluorouracil for First-Line Treatment in Patients with Advanced Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Pancreatic carcinoma

Recruiting

Study on the Effectiveness of Paclitaxel and Gemcitabine for Patients with Pancreatic Cancer Spread to the Abdomen

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.